Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


28.01.2019

1 Am J Clin Oncol
8 BJU Int
1 BMC Cancer
1 BMC Urol
1 Br J Cancer
1 Br J Radiol
2 Cancer Lett
1 Clin Cancer Res
7 Eur Urol
3 Int J Cancer
1 J Cell Physiol
1 J Natl Cancer Inst
17 J Urol
1 Magn Reson Med
1 N Engl J Med
1 Oncogene
1 PLoS Genet
1 PLoS One
2 Prog Urol
5 Prostate
2 Radiology
2 Ther Adv Urol
2 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Clin Oncol

  1. RICE SR, Olexa G, Hussain A, Mannuel H, et al
    A Phase II Study Evaluating Bone Marrow-Sparing, Image-guided Pelvic Intensity-Modulated Radiotherapy (IMRT) With Cesium-131 Brachytherapy Boost, Adjuvant Chemotherapy, and Long-Term Hormonal Ablation in Patients With High Risk, Nonmetastatic Prostate
    Am J Clin Oncol. 2019 Jan 22. doi: 10.1097/COC.0000000000000520.
    PubMed     Text format     Abstract available


    BJU Int

  2. REICHARD CA, Nyame YA, Sundi D, Tosoian J, et al
    Does time from diagnosis to treatment of high or very high risk prostate cancer affect outcome?
    BJU Int. 2019 Jan 17. doi: 10.1111/bju.14671.
    PubMed     Text format     Abstract available

  3. MA WK, Poon DM, Chan CK, Chan TW, et al
    Consensus statements on the management of clinically localised prostate cancer from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology.
    BJU Int. 2019 Jan 17. doi: 10.1111/bju.14681.
    PubMed     Text format     Abstract available

  4. SIGHINOLFI MC, Sandri M, Torricelli P, Ligabue G, et al
    External validation of a novel side-specific, multiparametric magnetic resonance imaging-based nomogram for the prediction of extracapsular extension of prostate cancer: preliminary outcomes on a series diagnosed with mpMRI targeted plus systematic sa
    BJU Int. 2019 Jan 18. doi: 10.1111/bju.14665.
    PubMed     Text format     Abstract available

  5. KRIMPHOVE MJ, Fletcher SA, Trinh QD
    Multiparametric magnetic resonance imaging for prostate cancer detection: do clinical trial findings reflect real-world practice?
    BJU Int. 2019;123:197-198.
    PubMed     Text format    

  6. ROSE BS
    Postoperative radiation and hormonal therapy for men with node-positive prostate cancer: a new standard?
    BJU Int. 2019;123:199-200.
    PubMed     Text format    

  7. LAVIANA AA, Penson DF
    Multiparametric magnetic resonance imaging (MRI) with targeted fusion biopsy: is the time now?
    BJU Int. 2018;122:1-2.
    PubMed     Text format    

  8. POPERT R
    Systematic transperineal and magnetic resonance imaging-targeted biopsies: the resolution of uncertainty.
    BJU Int. 2018;122:6-7.
    PubMed     Text format    

  9. SOOD A, Abdollah F, Menon M
    Robot-assisted radical prostatectomy and a parachute.
    BJU Int. 2018;121:820-821.
    PubMed     Text format    


    BMC Cancer

  10. CALAIS J, Czernin J, Fendler WP, Elashoff D, et al
    Correction to: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].
    BMC Cancer. 2019;19:97.
    PubMed     Text format     Abstract available


    BMC Urol

  11. HILGER C, Schostak M, Neubauer S, Magheli A, et al
    The importance of sexuality, changes in erectile functioning and its association with self-esteem in men with localized prostate cancer: data from an observational study.
    BMC Urol. 2019;19:9.
    PubMed     Text format     Abstract available


    Br J Cancer

  12. KAWAKITA D, Lee YA, Gren LH, Buys SS, et al
    The impact of folate intake on the risk of head and neck cancer in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort.
    Br J Cancer. 2017 Nov 21. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    Br J Radiol

  13. COHEN J, Anvari A, Samanta S, Poirier Y, et al
    Mild hyperthermia as a localized radiosensitizer for deep-seated tumors: Investigation in an orthotopic prostate cancer model in mice.
    Br J Radiol. 2019 Jan 23:20180759. doi: 10.1259/bjr.20180759.
    PubMed     Text format     Abstract available


    Cancer Lett

  14. CHEN Y, Gera L, Zhang S, Li X, et al
    Small Molecule BKM1972 Inhibits Human Prostate Cancer Growth and Overcomes Docetaxel Resistance in Intraosseous Models.
    Cancer Lett. 2019 Jan 17. pii: S0304-3835(19)30022.
    PubMed     Text format     Abstract available

  15. TIAN J, Guo F, Chen Y, Li Y, et al
    Nanoliposomal formulation encapsulating celecoxib and genistein inhibiting COX-2 pathway and Glut-1 receptors to prevent prostate cancer cell proliferation.
    Cancer Lett. 2019 Jan 20. pii: S0304-3835(19)30014.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  16. MOHAMMADPOUR H, Bucsek MJ, Hylander BL, Repasky EA, et al
    Depression stresses the immune response and promotes prostate cancer growth.
    Clin Cancer Res. 2019 Jan 22. pii: 1078-0432.CCR-18-3980.
    PubMed     Text format     Abstract available


    Eur Urol

  17. SATHIANATHEN NJ, Konety BR
    Reply to Diana A. Castillo-Jimenez and Herney A. Garcia-Perdomo's Letter to the Editor re: Niranjan J. Sathianathen, Badrinath R. Konety, Fernando Alarid-Escudero, Nathan Lawrentschuk, Damien M. Bolton, Karen M. Kuntz. Cost-effectiveness Analysis of A
    Eur Urol. 2019 Jan 18. pii: S0302-2838(19)30020.
    PubMed     Text format    

  18. CASTILLO-JIMENEZ DA, Garcia-Perdomo HA
    Re: Niranjan J. Sathianathen, Badrinath R. Konety, Fernando Alarid-Escudero, Nathan Lawrentschuk, Damien M. Bolton, Karen M. Kuntz. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer. Eur Urol. In press
    Eur Urol. 2019 Jan 18. pii: S0302-2838(19)30013.
    PubMed     Text format    

  19. COLE AP, Trinh QD
    Reply to Amar U. Kishan, William Hall, and Daniel Spratt's Letter to the Editor re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachyth
    Eur Urol. 2019 Jan 19. pii: S0302-2838(19)30018.
    PubMed     Text format    

  20. KISHAN AU, Hall WA, Spratt DE
    Re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. Eur Urol. In press.
    Eur Urol. 2019 Jan 19. pii: S0302-2838(19)30017.
    PubMed     Text format    

  21. GHADJAR P, Wiegel T
    Re: Abdenour Nabid, Nathalie Carrier, Andre-Guy Martin, et al. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. Eur Urol 2018;74:432-31.
    Eur Urol. 2018 Oct 26. pii: S0302-2838(18)30818.
    PubMed     Text format    

  22. ON BEHALF OF EMA
    Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James, et al.'s Letter to the Editor re: The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eu
    Eur Urol. 2019 Jan 15. pii: S0302-2838(18)30957.
    PubMed     Text format    

  23. SEMJONOW A, Hense HW, Schlossler K, Simbrich A, et al
    Development and Prospective Randomized Evaluation of a Decision Aid for Prostate-specific Antigen-based Early Detection of Prostate Cancer in Men Aged Between 55 and 69Yr: The PSAInForm Trial.
    Eur Urol. 2019 Jan 18. pii: S0302-2838(19)30009.
    PubMed     Text format     Abstract available


    Int J Cancer

  24. BAO C, Pedersen NL, Yang R, Marseglia A, et al
    Diabetes in midlife and risk of cancer in late life: A nationwide Swedish twin study.
    Int J Cancer. 2018;143:793-800.
    PubMed     Text format     Abstract available

  25. LINDBERG A, Talala K, Kujala P, Stenman UH, et al
    Bias-corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: Analysis of the Finnish Randomized Study of Screening for Prostate Cancer.
    Int J Cancer. 2019 Jan 17. doi: 10.1002/ijc.32129.
    PubMed     Text format     Abstract available

  26. WENDEU-FOYET MG, Koudou Y, Cenee S, Tretarre B, et al
    Circadian genes and risk of prostate cancer: findings from the EPICAP study.
    Int J Cancer. 2019 Jan 21. doi: 10.1002/ijc.32149.
    PubMed     Text format     Abstract available


    J Cell Physiol

  27. MUTHUSWAMI R, Bailey L, Rakesh R, Imbalzano AN, et al
    BRG1 is a prognostic indicator and a potential therapeutic target for prostate cancer.
    J Cell Physiol. 2019 Jan 22. doi: 10.1002/jcp.28161.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  28. DONDOSSOLA E, Casarin S, Paindelli C, De-Juan-Pardo EM, et al
    Radium 223-mediated zonal cytotoxicity of prostate cancer in bone.
    J Natl Cancer Inst. 2019 Jan 18. pii: 5292474. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Urol

  29. LUDWIG WW, Feng Z, Trock BJ, Humphreys E, et al
    Prostate Specific Antigen Testing after Radical Prostatectomy-Can We Stop at 20 Years?
    J Urol. 2018;199:114-119.
    PubMed     Text format     Abstract available

  30. TETREAULT-LAFLAMME A, Crook J, Hamm J, Pickles T, et al
    Long-Term Prostate Specific Antigen Stability and Predictive Factors of Failure after Permanent Seed Prostate Brachytherapy.
    J Urol. 2018;199:120-125.
    PubMed     Text format     Abstract available

  31. KAPOOR DA
    A History of the United States Preventive Services Task Force: Its Expanding Authority and Need for Reform.
    J Urol. 2018;199:37-39.
    PubMed     Text format    

  32. BHINDI B
    Editorial Comment.
    J Urol. 2018;199:87-88.
    PubMed     Text format    

  33. NAHAR B, Parekh DJ
    Editorial Comment.
    J Urol. 2018;199:138.
    PubMed     Text format    

  34. PATEL NA, Kasabwala K, Hu JC
    Editorial Comment.
    J Urol. 2018;199:138-139.
    PubMed     Text format    

  35. BURNS JF, Hurwitz LM, Levie KE, Caumont F, et al
    Impact of Subsequent Biopsies on Comprehensive Health Related Quality of Life in Patients With and Without Prostate Cancer.
    J Urol. 2019 Jan 25. doi: 10.1097/JU.0000000000000024.
    PubMed     Text format     Abstract available

  36. YAXLEY JW, Raveenthiran S, Nouhaud FX, Samartunga H, et al
    Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with 68Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology: Can Preoperative 68Ga-PSMA Po
    J Urol. 2019 Jan 21. doi: 10.1097/JU.0000000000000053.
    PubMed     Text format     Abstract available

  37. SALARI K, Kuppermann D, Preston MA, Dahl DM, et al
    Active Surveillance of Prostate Cancer is a Viable Option in Men Younger Than 60 Years.
    J Urol. 2019 Jan 16. doi: 10.1097/JU.0000000000000031.
    PubMed     Text format     Abstract available

  38. TANEJA SS
    Re: Transcriptomic Heterogeneity in Multifocal Prostate Cancer.
    J Urol. 2019 Jan 15. doi: 10.1097/JU.0000000000000101.
    PubMed     Text format    

  39. TANEJA SS
    Re: Olaparib Combined with Abiraterone in Patients with Metastatic Castration-Resistant Prostate Cancer: .
    J Urol. 2019 Jan 15. doi: 10.1097/01.JU.0000553310.60445.
    PubMed     Text format    

  40. ATALA A
    Re: Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import.
    J Urol. 2019 Jan 15. doi: 10.1097/JU.0000000000000096.
    PubMed     Text format    

  41. ZHAO J, Liu J, Sun G, Zhang M, et al
    The Prognostic Value of the Proportion and Architectural Patterns of Intraductal Carcinoma of the Prostate in Patients with de Novo Metastatic Prostate Cancer.
    J Urol. 2019 Jan 15. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available

  42. SALAMI SS
    Editorial Comment.
    J Urol. 2018;199:104.
    PubMed     Text format    

  43. JOHNSON DC, Litwin MS
    Editorial Comment.
    J Urol. 2018;199:96.
    PubMed     Text format    

  44. GHANI KR, Miller DC, Montie JE
    Editorial Comment.
    J Urol. 2018;199:96-97.
    PubMed     Text format    

  45. SONN G
    Editorial Comment.
    J Urol. 2018;199:104-105.
    PubMed     Text format    


    Magn Reson Med

  46. KLAWER EME, van Houdt PJ, Simonis FFJ, van den Berg CAT, et al
    Improved repeatability of dynamic contrast-enhanced MRI using the complex MRI signal to derive arterial input functions: a test-retest study in prostate cancer patients.
    Magn Reson Med. 2019 Jan 17. doi: 10.1002/mrm.27646.
    PubMed     Text format     Abstract available


    N Engl J Med

  47. GOODMAN PJ, Tangen CM, Darke AK, Lucia MS, et al
    Long-Term Effects of Finasteride on Prostate Cancer Mortality.
    N Engl J Med. 2019;380:393-394.
    PubMed     Text format    


    Oncogene

  48. COMITO G, Iscaro A, Bacci M, Morandi A, et al
    Lactate modulates CD4(+) T-cell polarization and induces an immunosuppressive environment, which sustains prostate carcinoma progression via TLR8/miR21 axis.
    Oncogene. 2019 Jan 21. pii: 10.1038/s41388-019-0688.
    PubMed     Text format     Abstract available


    PLoS Genet

  49. CANNATARO VL, Townsend JP
    Wagging the long tail of drivers of prostate cancer.
    PLoS Genet. 2019;15:e1007820.
    PubMed     Text format    


    PLoS One

  50. GUPTA S, Silveira DA, Mombach JCM
    Modeling the role of microRNA-449a in the regulation of the G2/M cell cycle checkpoint in prostate LNCaP cells under ionizing radiation.
    PLoS One. 2018;13:e0200768.
    PubMed     Text format     Abstract available


    Prog Urol

  51. MEUNIER ME, Neuzillet Y, Radulescu C, Cherbonnier C, et al
    [Does the delay from prostate biopsy to radical prostatectomy influence the risk of biochemical recurrence?]
    Prog Urol. 2018;28:475-481.
    PubMed     Text format     Abstract available

  52. GURY L, Robert G, Bensadoun H
    [Where do we stand with benign prostatic hyperplasia day-case surgery: A laser effect?]
    Prog Urol. 2018 Jun 12. pii: S1166-7087(18)30121.
    PubMed     Text format     Abstract available


    Prostate

  53. GHINEA N, Robin B, Pichon C, Leclere R, et al
    Vasa nervorum angiogenesis in prostate cancer with perineural invasion.
    Prostate. 2019 Jan 20. doi: 10.1002/pros.23771.
    PubMed     Text format     Abstract available

  54. CHOI YH, Han DH, Kim SW, Kim MJ, et al
    A randomized, double-blind, placebo-controlled trial to evaluate the role of curcumin in prostate cancer patients with intermittent androgen deprivation.
    Prostate. 2019 Jan 22. doi: 10.1002/pros.23766.
    PubMed     Text format     Abstract available

  55. JOENTAUSTA RM, Rannikko A, Murtola TJ
    Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort.
    Prostate. 2019 Jan 16. doi: 10.1002/pros.23768.
    PubMed     Text format     Abstract available

  56. LI C, He C, Xu Y, Xu H, et al
    Alternol eliminates excessive ATP production by disturbing Krebs cycle in prostate cancer.
    Prostate. 2019 Jan 20. doi: 10.1002/pros.23767.
    PubMed     Text format     Abstract available

  57. PETRYLAK DP, Kantoff P, Vogelzang NJ, Mega A, et al
    Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer.
    Prostate. 2019 Jan 20. doi: 10.1002/pros.23765.
    PubMed     Text format     Abstract available


    Radiology

  58. EBERHARDT SC
    Local Staging of Prostate Cancer with MRI: A Need for Standardization.
    Radiology. 2019 Jan 22:182943. doi: 10.1148/radiol.2019182943.
    PubMed     Text format    

  59. MEHRALIVAND S, Shih JH, Harmon S, Smith C, et al
    A Grading System for the Assessment of Risk of Extraprostatic Extension of Prostate Cancer at Multiparametric MRI.
    Radiology. 2019 Jan 22:181278. doi: 10.1148/radiol.2018181278.
    PubMed     Text format     Abstract available


    Ther Adv Urol

  60. PURSHOUSE K, Protheroe AS
    Abiraterone acetate in combination with prednisone in the treatment of metastatic hormone-sensitive prostate cancer: clinical evidence and experience.
    Ther Adv Urol. 2019;11:1756287218820804.
    PubMed     Text format     Abstract available

  61. MOGHUL M, Somani B, Lane T, Vasdev N, et al
    Detection rates of recurrent prostate cancer: (68)Gallium (Ga)-labelled prostate-specific membrane antigen versus choline PET/CT scans. A systematic review.
    Ther Adv Urol. 2019;11:1756287218815793.
    PubMed     Text format     Abstract available


    Urology

  62. ZHOU SR, Simopoulos DN, Jayadevan R, Felker ER, et al
    USE OF MRI-GUIDED BIOPSY FOR SELECTION AND FOLLOW-UP OF MEN UNDERGOING HEMI-GLAND CRYOABLATION OF PROSTATE CANCER.
    Urology. 2019 Jan 16. pii: S0090-4295(19)30058.
    PubMed     Text format     Abstract available

  63. PIKE LRG, Wu J, Chen MH, Loffredo M, et al
    Time to PSA Nadir and the Risk of Death from Prostate Cancer following Radiation and Androgen Deprivation Therapy.
    Urology. 2019 Jan 18. pii: S0090-4295(19)30066.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: